AstraZeneca Pharma India Secures CDSCO Approval for New Cancer Treatment
AstraZeneca Pharma India Ltd has received crucial approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute its cancer treatment medication, Durvalumab. This announcement was made on March 3, 2025, paving the way for the marketing of this critical therapy in the Indian market.
The CDSCO has granted permission for the infusion solutions of Durvalumab, available in 120 mg/2.4 ml and 500 mg/10 ml formulations, known commercially as Imfinzi. This approval allows AstraZeneca to promote Durvalumab in combination with Tremelimumab for treating patients with unresectable hepatocellular carcinoma (uHCC).
This regulatory clearance is a significant milestone for AstraZeneca as it expands its oncology portfolio in India, addressing the needs of patients suffering from this aggressive form of liver cancer. The company is now set to proceed with marketing these solutions, contingent upon obtaining all necessary statutory approvals.
As the demand for effective cancer treatments continues to rise, AstraZeneca’s expansion of its offerings in India underscores its commitment to improving healthcare outcomes for patients battling cancer.
You May Interested In
2026-10-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Univar Solutions Expands Partnership with American Distilling in EMEA to Strengthen Natural Specialty Ingredients Distribution Network
-
Behind Starbucks China’s Ownership Change: The Race for Localization and Efficiency
-
Wanhua’s Counter-Cyclical Expansion: A Gamble or a Strategic Move for the Next Cycle?
-
Is Evonik’s Massive Global Expansion of Hydroxyl-Terminated Polybutadiene (HTPB) a Technological Ambition — or a Geopolitical Gamble?
-
BASF Builds New Alkyl Polyglucoside Plant in Thailand, Expands Its Business Footprint in Asia
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
US Chemical Shutdown Wave Expands, PS Units Become the Hardest Hit Segment
-
Covestro Builds New 660,000-ton MDI Plant in China: Global Supply Gap Meets Chinese Overcapacity Head-On
-
$2.43 Billion Deal: Olin Buys Huntsman
-
Advent Drops Its 2026 Purchase, and LANXESS’s €1.2 Billion Exit Plan Falls Through
Recommend Reading
-
![Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard]()
Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard
-
![Biochem to Acquire BASF’s Global Glycinates Business]()
Biochem to Acquire BASF’s Global Glycinates Business
-
![BASF increases prices for MDI in ASEAN countries]()
BASF increases prices for MDI in ASEAN countries
-
![Dow Chemical Weighs Exit from $20 Billion Chemical Joint Venture with Saudi Aramco]()
Dow Chemical Weighs Exit from $20 Billion Chemical Joint Venture with Saudi Aramco
-
![Losses Persist, Yet Huntsman Raises Prices — A Quiet Turning Point in the MDI Cycle]()
Losses Persist, Yet Huntsman Raises Prices — A Quiet Turning Point in the MDI Cycle
-
![Business Society’s PVC Market Outlook on September 10, 2026: Upside Limited]()
Business Society’s PVC Market Outlook on September 10, 2026: Upside Limited
-
![This Week's Titanium Dioxide Prices in China Decline (8.17-8.21)]()
This Week's Titanium Dioxide Prices in China Decline (8.17-8.21)
-
![Zimbabwe Suspends Lithium Export, Lithium Carbonate Prices Rise]()
Zimbabwe Suspends Lithium Export, Lithium Carbonate Prices Rise
-
![Business Society’s Market Outlook for Caustic Soda on September 10, 2026: Downside Limited]()
Business Society’s Market Outlook for Caustic Soda on September 10, 2026: Downside Limited
-
![Ammonium Sulfate Prices Continue to Firmly Rise (4.1-4.8)]()
Ammonium Sulfate Prices Continue to Firmly Rise (4.1-4.8)
